Global, regional and country-level 90–90–90 estimates for 2018: assessing progress towards the 2020 target : AIDS

Secondary Logo

Journal Logo


Global, regional and country-level 90–90–90 estimates for 2018

assessing progress towards the 2020 target

Marsh, Kimberlya; Eaton, Jeffrey W.b; Mahy, Marya; Sabin, Keitha; Autenrieth, Christine S.a; Wanyeki, Iana; Daher, Julianaa; Ghys, Peter D.a

Author Information
doi: 10.1097/QAD.0000000000002355



Over the last two decades, a growing number of studies in diverse settings have demonstrated that antiretroviral treatment (ART) can play a dual role in improving the health of people living with HIV (PLHIV) and reducing onward transmission [1–7]. The Joint United Nations Programme on HIV and AIDS (UNAIDS) and the WHO have encouraged countries and global partners to translate evidence of ART's benefits from research studies into routine practice through a series of increasingly ambitious target setting initiatives [8,9]. With the goal of ending the AIDS epidemic by 2030, UNAIDS launched the 90–90–90 target in 2014: by 2020, 90% of PLHIV know their HIV status; 90% of all people with diagnosed HIV infection are on antiretroviral therapy; and 90% of people accessing treatment have suppressed viral load [10]. Mathematical modelling suggests that front-loading resources to reach 90–90–90 by 2020, with a further increase to 95–95–95 and the scale-up of other prevention measures by 2030, can reduce new HIV infections and AIDS deaths worldwide by 90% between 2010 and 2030 [11].

Routinely assessing country-level, regional and global progress towards 90–90–90 is critical to determining progress. Identifying gaps can help countries make necessary course-corrections to improve and expand service delivery where needed. However, studies have highlighted the many challenges of monitoring progress towards 90–90–90 in the early years of the initiative, including discrepancies in reported data, limited data availability in the public domain and lack of cross-country comparability of cascades [12,13]. Since 2015, countries have reported annually to UNAIDS on each prong of the 90–90–90 target following standardized reporting methodologies, including revising historical data as needed [14]. In this article, we describe these reporting methods and the data submitted to UNAIDS through 2018 (the latest reporting year). We also report national-level achievements and estimates of global and regional progress towards the 2020 target overall and by sex for adults 15 years of age and older.


Data sources and methods for constructing national measures of 90–90–90

We used the latest modelled estimates of PLHIV and data provided annually by 170 countries to UNAIDS for the years 2015–2018 on the estimated numbers of PLHIV who know their HIV status, who are on treatment and who are virally suppressed to construct national measures of progress towards 90–90–90. The 170 countries that contribute to UNAIDS global HIV estimates represent approximately 99% of the total 2018 population worldwide.

Progress towards 90–90–90 and the HIV testing cascade (measured as a proportion of all PLHIV) was calculated as described in Table 1. Where available, estimates were calculated separately for children (0–14 years) and adults (15 years and older by sex) and aggregated across all age groups.

Table 1:
90–90–90 Definitions and targets.

Standard methods and accepted sources for reporting against the 90–90–90 target have been published by UNAIDS since 2016 and are described briefly below. Additional methodological considerations are found in the 2019 Global AIDS Monitoring guidelines [14].

People living with HIV estimates

Most countries reported mid-year estimates of the number of PLHIV by age and sex using the Spectrum modelling tool. For a small number of countries, primarily in high-income countries in Europe, Brazil and the United States, as well as in South Africa, other bespoke models are used to estimate PLHIV and Spectrum files are developed to match the modelled results [15–17]. Published country estimates of the number of PLHIV in 2018 were available for 79% of the estimated total PLHIV worldwide. More detail on using Spectrum to estimate the number of PLHIV can be found elsewhere in this supplement [18,19].

People living with HIV who know their HIV status

Countries used one of three different methods to report on the number of PLHIV who know their status at end-year. Most countries in sub-Saharan Africa used a UNAIDS supported ‘Shiny90’ model to estimate this outcome for the current year and for historical trends from 2010 [20]. The model uses HIV incidence, prevalence and ART coverage from the national Spectrum file, data about the proportion ever tested for HIV by HIV status from national population surveys, and where available, HIV testing and positivity programme data to estimate the proportion of PLHIV aware of their status over time. More details on this approach are provided elsewhere in this supplement [20].

Estimates in most countries outside of sub-Saharan Africa were calculated directly from HIV surveillance systems by subtracting the cumulative number of deaths among people diagnosed with HIV from the cumulative number of people diagnosed. To use this method, the national HIV surveillance system should have been functioning since at least 2013 and people who died, emigrated or who otherwise were lost to follow-up must be removed. In a third approach used by selected countries in Europe and North America, incidence, prevalence and the proportion of the undiagnosed population was modelled from case surveillance data, clinical information about disease progression and assumptions around HIV diagnoses rates [15,17].

People on treatment

Data on the number of people on treatment at the end of the reporting year were typically abstracted from routine health information systems, monthly programme reports, pharmaceutical records or from case surveillance systems by the country teams that work on HIV estimates. Since treatment numbers are critical to estimating PLHIV, AIDS mortality and other impact indicators accurately in Spectrum, these data are available for almost all 170 countries. For a small number of countries where reported numbers of people on treatment were not available from programme data – primarily in western and central Europe and North America – estimates of the number of people on treatment were developed either in consultation with the public health agency responsible for monitoring the national treatment programme or based on other published sources.

People virally suppressed

Estimates of the number of people suppressed at end-year were primarily collected from laboratory, case surveillance or programme reports. Some countries may triangulate programme data with direct measures from national population-based or HIV drug resistance surveys in the survey year. The reporting threshold for suppression is less than 1000 copies/ml, although some countries report against lower thresholds [21]. Currently, UNAIDS recommends that countries with viral load testing coverage between 50% and 90% assume that viral suppression in the untested and tested populations are the same when calculating suppression levels among all people on treatment. Above 90%, no further adjustments are required because testing is assumed to be universally available.

Exclusion criteria for country-submitted data

Country-provided data that do not meet basic checks for internal consistency across the cascade (e.g. the number of people who know their status exceeded the number of PLHIV) or that are unexplainably inconsistent with other reporting sources (e.g. the number of people reported to be virally suppressed by the Ministry of Health was lower than national population survey estimates during the same time period) were excluded. Viral load suppression results from routine programme data were only included for countries where access to routine testing was performed for at least 50% of PLHIV on ART.

Uncertainty around country estimates of 90–90–90

Upper and lower ranges of uncertainty for country-level estimates were calculated from the range of estimated numbers of PLHIV. This range does not fully capture uncertainty in the numbers of people who know their HIV status, who are on treatment and who are virally suppressed. Uncertainty in these data will vary by country and data source.

Methods for estimating regional and global progress towards 90–90–90

To calculate regional and global estimates of 90–90–90, a Bayesian hierarchical model based on regional trends, sex differences and country data (where countries reported data for some but not all years) was used to impute missing data for the first and third 90s. Estimates of knowledge of status were imputed in two steps. First, the logit of the proportion aware among PLHIV not on treatment was modelled using a two-level hierarchical structure with fixed effects for linear time trend and age-sex (children 0–14 years of age, men 15 years of age and older, women 15 years of age and older), region-level random effects for intercept, time trend and age-sex, and country-level random intercepts and age-sex effects. Second, the estimated proportion of PLHIV aware of status in this population was added to the proportion on treatment. To impute missing viral load suppression data for the third 90, the logit of viral suppression was modelled using the same two-level hierarchical model used to estimate knowledge of status. Posterior distributions for each 90 were estimated using the ‘rstanarm’ package for applied Bayesian regression modelling in the Statistical software R (R Foundation for Statistical Computing, Vienna, Austria) [22].

For each imputed country estimate of either the first or third 90, 2000 values were drawn from the posterior distribution. Regional and global averages and trends were calculated by combining the 2000 draws with available country data. Given the significantly higher proportion of people virally suppressed in western and central Europe compared with the United States for the years in which data were available, subregional estimates for North America and western and central Europe were separately determined and then combined to produce the results for the region of western and central Europe and North America. Table S1 shows the proportion of imputed estimates for the first and third 90 between 2015 and 2018;

Upper and lower global and regional uncertainty ranges were calculated using the uncertainty in the number of PLHIV and from missing data. Uncertainty in treatment numbers of a 4% under-report or a 12% over-report was incorporated into uncertainty in the second and third 90s and ART coverage. These values were constructed from published and unpublished data quality reviews made available to UNAIDS prior to 2017 [23,24].


Country progress towards 90–90–90

Complete HIV testing and treatment data to monitor 90–90–90 were available for 75 of the 170 countries in at least one of the four reporting years between 2015 and 2018. Sixty countries had complete cascades as of 2018 (Table 2). The number of countries able to report on any one prong of 90–90–90 increased substantially across reporting years, although viral suppression data were still available in only 76 countries in 2018.

Table 2:
Data availability for constructing national progress towards the 90–90–90 treatment target, by region, 2015–2018.

Country progress towards 90–90–90 varied across regions and over time (refer to Table 3 for 2018 outcomes and Table S1 for 2015–2018 results; The latest country data through 2018 show that 15 countries reported meeting the viral suppression target among all PLHIV of 73%. These included Australia, Botswana, Cambodia, Denmark, Eswatini, France, Germany, Iceland, Ireland, Namibia, Netherlands, Rwanda, Spain, Thailand and the United Kingdom. Among these, six countries reported achieving each of the 90–90–90 prongs, including three countries (Botswana, Eswatini and Namibia) in southern Africa. For countries able to report in 2015 and 2018, 10 (Comoros, Guyana, Armenia, Tajikistan, Thailand, Cote d’Ivoire, Mexico, Morocco, Niger and Kuwait) had absolute increases in knowledge of status of 10 percentage points or more, 44 had made similar gains for the second 90, and despite the fact that treatment suppression among people on treatment was already reasonably high in most countries even in 2015, a few counties such as Uruguay and Armenia reported substantial gains of over 10 percentage points or more during the four years. UNAIDS’ website ( provides additional country-level disaggregated outcomes for 90–90–90 and the cascade among adults by sex and children.

Table 3:
Progress towards 90–90–90 and the HIV testing and treatment cascade, all ages, by country, region and global, 2018.a
Table 3:
(Continued) Progress towards 90–90–90 and the HIV testing and treatment cascade, all ages, by country, region and global, 2018.a
Table 3:
(Continued) Progress towards 90–90–90 and the HIV testing and treatment cascade, all ages, by country, region and global, 2018.a
Table 3:
(Continued) Progress towards 90–90–90 and the HIV testing and treatment cascade, all ages, by country, region and global, 2018.a

Global and regional progress towards 90–90–90

In 2018, an estimated eight of 10 (79%; 67– 92%) PLHIV globally knew their HIV status. Among them, 78% (69– 82%) were accessing antiretroviral therapy, and 86% (72–92%) of people accessing treatment had suppressed viral loads (Fig. 1a). Although the number of people who know their HIV status and are on treatment has risen steadily between 2015 and 2018, viral suppression among those on treatment has remained relatively stable.

Fig. 1:
(a) Progress towards 90–90–90, all ages and by sex for adults 15 years of age and older, global, 2018. (b) Progress along the HIV testing and treatment cascade, all ages, global, 2015–2018.

Of the 37.9 million (32.7–44.0 million) PLHIV globally, 62% (46–74%) were on treatment and over half [53% (42–63%)] had suppressed viral loads (Fig. 1b). Despite steady gains in treatment coverage reaching 23.3 million (20.5-24.3 million) in 2018, an annual increase of more than 3.3 million per year would be required to meet the 81% target for 2020. Average year-on-year increases since 2015 have been 2.0 million. The gap to fully achieving the global target of 73% of all PLHIV with suppressed viral load was 7.7 million people in 2018, down from more than 12 million people in 2015.

There was substantial variation by region and by sex (Fig. 2). In Asia and the Pacific and the Caribbean, eastern Europe and central Asia, the Middle East and North Africa and western and central Africa, treatment coverage and viral suppression gaps as a proportion of all PLHIV remain large. In the Middle East and North Africa, the region with the poorest performance, among all PLHIV, less than half (47%; 26–80%) know their status, 29% (17–43%) were accessing antiretroviral therapy and 22% (13–32%) had suppressed viral load.

Fig. 2:
HIV testing and treatment cascade, by region, 2018.

In contrast, the high-income region of western and central Europe and North America has nearly reached the target. Within this region, viral load suppression was near or above the first 90 threshold except in the United States, where the latest 2016 data showed low levels of viral load suppression among persons with diagnosed HIV infection [25,26]. In addition to the region of Western and central Europe and North America, eastern and southern Africa has made impressive gains toward the 90–90–90 target, with viral load suppression among all PLHIV increasing from 43% (37–50%) in 2015 to 58% (50–64%) in 2018. Latin America also appears to be moving towards achieving the 2020 viral suppression target at 55% (42–69%). Notably, though, progress has been slower in Latin America than eastern and southern Africa. Both regions had the same suppression levels among PLHIV in 2015.

Across all reporting years, estimates of all three 90s are lower for men than women, although these disparities are most pronounced in the first and second 90s (Fig. 1a). Regional variations are also evident. Knowledge of status among men is a full 20 percentage points lower than estimates among women in Eastern Europe and Central Asia and between 10 and 15% lower than the estimate among women in the Caribbean and western and central Africa. A comparison of trends between 2010 and 2018 for men and women in eastern and southern Africa and western and central Africa show men in the western and central African countries lagging the furthest behind in knowledge of status in recent years (Fig. 3). In Latin America and western and central Europe and North America, similar achievements by sex were observed for all three 90s.

Fig. 3:
Knowledge of HIV status among people living with HIV, by sex, Eastern and Southern Africa and Western and Central Africa, 2010–2018.

Among children, estimates of knowledge of status are not available but for the remaining cascade, treatment coverage among children is 54% (37–73%) versus 62% (48–75%) among adults and viral suppression among children is just 41% (26–56%) versus 53% (44–63%) among adults. Intensive efforts in Eswatini, Namibia, Zambia and Zimbabwe have led to paediatric treatment levels of over 75%; however, elsewhere, especially in countries in western and central Africa, the disparity between adult and child treatment coverage is growing.


The global commitment to scaling-up HIV testing and treatment programmes has accelerated the pace at which the world is moving to achieve 90–90–90. Despite this progress, it seems unlikely that many regions and countries will meet the 2020 target. As of 2018, approximately one in five PLHIV globally still do not know their HIV status, a further 22% of those who know their status are not accessing antiretroviral therapy and 14% of people on treatment do not yet have a suppressed viral load. Even with an absolute increase in the number of people on treatment from 15.1 million (13.3-15.7 million) in 2014 to 23.3 million (20.5-24.3 million) in 2018, the pace at which people access treatment needs to be even faster. Only modest improvements in viral suppression levels among people on treatment have been observed since the launch of the 90–90–90 target in contrast with the more substantial gains in knowledge of HIV status.

For many countries and regions, and within key subpopulations, examination of progress towards the 90–90–90 target and the gaps have provided useful information about what programme delivery improvements are needed [2,27–31]. Even in countries and regions where overall progress towards 73% viral load suppression among PLHIV has been achieved, including Namibia and Botswana, a significantly higher proportion of men are still unaware of their HIV status compared with women. In the Russian Federation, which has the largest burden of HIV in Eastern Europe and central Asia, knowledge of status in previously reported estimates was thought to be high as a result of extensive testing, but linkage to treatment remains a challenge [32,33]. In the Middle East and North Africa, persistently low estimates of knowledge of HIV status and treatment access point to the role of stigma and discrimination in service delivery as possible causes [34,35]. For those who do overcome barriers to learning their status and initiating treatment, viral suppression levels in these regions are on par with high performing regions.

To reach the remaining groups of PLHIV who still do not know their status, innovative testing approaches, such as self-testing, index testing and delivery of testing through community-based services, will be required [36]. In generalized epidemics, these services are increasingly designed to reach people who otherwise might not seek HIV testing in health facilities, especially men and young people, as well as key population members and their partners. In concentrated epidemics, where HIV infections occur primarily in key populations and their partners, an optimized mix of routine and targeted testing services is needed. As more and more countries reach the 90–90–90 target, improved methods are needed to accurately collect information on how people may have acquired their infection to estimate progress towards the target among key populations [37].

With an additional 6.7 million people needing treatment by 2020 to meet the target, rapid expansion of proven models to get diagnosed individuals into care and, increasingly important, keep them on treatment are needed. Most countries have already benefitted from the treatment bump that stemmed from the early political and financial commitments from the U.S. Government President's Emergency Program for AIDS Relief (PEPFAR) and the Global Fund for AIDS, Tuberculosis and Malaria (Global Fund) [38]. Although near universal adoption of WHO's recommendation to ‘treat all’ by countries in 2016 has increased those who are eligible for ART [21], the rate of annual increase in numbers of people on treatment has not accelerated in recent years. In the SEARCH and HPTN071 (PopART) studies showed that using trained community health workers and providing an array of health services beyond HIV enable communities to reach the second 90 in sub-Saharan Africa [39,40]. Closing the ART coverage gap for children will require programmes that reach children after well child care visits end [11,12]. Finally, healthcare services need a user-friendly approach to supporting treatment among key populations who may feel stigmatized by healthcare workers when accessing testing and treatment services [13].

The modest gains in viral suppression through 2018 highlight the need for new strategies to support adherence and regimen switching when treatment failure is suspected. Although the availability of new medicines such as dolutegravir that offer a faster and sustained pathway to viral suppression (even among those who fail with older integrase inhibitors) will help, community-centred activities to help support adherence to treatment are paramount [2,41]. Strategies that use peers and trained community health workers have been shown to produce retention rates and treatment outcomes on par with those reported in traditional healthcare delivery settings [42–44]. Viral load testing is critical to identify patients who do not have suppressed viral load and initiate adherence support or a switch to second-line or third-line therapy, as appropriate.

Using the 90–90–90 estimates to identify and close gaps along the cascade requires tools that allow countries to accurately track outcomes. However, current approaches are subject to a number of potential limitations. For example, estimates across the cascade based on programme service registers may be understated if these registers are incomplete, or conversely, overstated if duplicate data are not detected and deleted. In addition, if people die or emigrate but are not removed from counts, achievements could be exaggerated. Many countries have recognized the potential for these inconsistencies and are actively taking steps to improve reporting systems. Between 2017 and 2019, most countries in sub-Saharan Africa have conducted or are in the process of conducting national data quality reviews using a standardized protocol to validate and correct current and historical treatment numbers where necessary [45]. The reported treatment numbers through 2018 are the first that incorporate results from these reviews.

Model-based national estimates of 90–90–90 (in particular for the first 90) also have been useful to assess country progress, although these approaches would benefit from further refinements. The new first 90 estimation model for sub-Saharan African, which triangulates data from HIV testing programmes and survey data about HIV testing history by age and sex, has markedly increased the availability of plausible estimates in the region, but more country-specific data on HIV testing and retesting behaviours is needed to validate expected yield (i.e. the number of truly new diagnoses) among those testing positive. In countries outside of sub-Saharan Africa where modelled estimates of the first 90 are based on case reports, data on CD4+ cell count at diagnosis is critical to estimating the unreported fraction; in 42 countries in the WHO European Region, however, these data were reported in just 67% of diagnosed cases in 2017 [46]. In 2019, the European Centres for Disease Control developed an online tool that countries can use to impute missing values such as CD4+ cell count to improve modelled estimates. Improved methods to estimate viral suppression in countries where testing access is limited are also needed.

Challenges also exist in accurately monitoring global and regional 90s. In previous years, estimates of progress in countries missing data was done using the ratio of knowledge of status and treatment for the first 90 and the ratio of the number of people suppressed among those on treatment in the region for countries where data were available. Because countries did not report in every year, however, these ratios fluctuated depending on the reporting year, making it difficult to compare trends over time. A benefit of the new hierarchical approach is that it can use reported data in whatever year they are available to estimate trends in and across the region. As with the previous approach, one primary limitation is that it is difficult to assess whether progress in countries with data is similar to that of countries without data. This is particularly true for viral load suppression estimates, where reported data in some regions including the Caribbean and Asia and Pacific – especially in 2015 and 2016 – are limited. As access to viral load testing improves over time, the accuracy of the estimates of the third 90 will improve.

While estimating progress towards 90–90–90 at all levels remain a challenge, the reported achievements have become the hallmark for measuring the success of the HIV response. Even after 2020, the framework of the 90–90–90 target remain paramount, signalling where additional investments and innovations in HIV testing and treatment programmes are needed to end the AIDS epidemic by 2030. The urgency over the next few years to focus on continued strengthening of systems and improved methods that will permit countries to accurately monitor these targets should not be underestimated.


All authors contributed to the indicator definitions and monitoring methods of the 90–90–90 target. K.M., M.M., K.S. and I.W. validated 2018 country-reported data. K.M., J.E., M.M. and C.A. produced the historical and current global and regional estimates. J.D. provides database management and validation support of the country-provided data. All authors contributed to the writing and review of the manuscript. The authors acknowledge the work of each of the country teams that developed and reported estimates to UNAIDS.

Conflicts of interest

There are no conflicts of interest.


1. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339:966–971.
2. Nachega JB, Sam-Agudu NA, Mofenson LM, Schechter M, Mellors JW. Achieving viral suppression in 90% of people living with human immunodeficiency virus on antiretroviral therapy in low- and middle-income countries: progress, challenges, and opportunities. Clin Infect Dis 2018; 66:1487–1491.
3. Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS 2012; 7:99–105.
4. Nosyk B, Audoin B, Beyrer C, Cahn P, Granich R, Havlir D, et al. Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS 2013; 27:1159–1165.
5. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397–1404.
6. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921–929.
7. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 2014; 14:281–290.
8. World Health Organization. World Health Organization. World Health Organization, Treat 3 million by 2005 initiative. Treating 3 million by 2005: making it happen: the WHO and UNAIDS global initiative to provide antiretroviral therapy to 3 million people with HIV/AIDS in developing countries by the end of 2005. Geneva, Switzerland: 2003.
9. General Assembly resolution 65/277. Political declaration on HIV/AIDS: intensifying our efforts to eliminate HIV/AIDS, A/RES/65/277 In; 10 June 2011.
10. Joint United Nationas Programme on HIV/AIDS (UNAIDS). 90–90–90: an ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nationas Programme on HIV/AIDS (UNAIDS); 2014.
11. Stover J, Bollinger L, Izazola JA, Loures L, DeLay P, Ghys PD, et al. What is required to end the AIDS epidemic as a public health threat by 2030? The cost and impact of the fast-track approach. PLoS One 2016; 11:e0154893.
12. Granich R, Gupta S, Hall I, Aberle-Grasse J, Hader S, Mermin J. Status and methodology of publicly available national HIV care continua and 90–90–90 targets: a systematic review. PLoS Med 2017; 14:e1002253.
13. Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90–90–90 target be achieved? A systematic analysis of national HIV treatment cascades. BMJ Global Health 2016; 1:e000010.
14. Joint United Nationas Programme on HIV/AIDS (UNAIDS). Global AIDS monitoring 2019: indicators for monitoring the 2016 political declaration on ending AIDS. Geneva: Joint United Nationas Programme on HIV/AIDS (UNAIDS); 2019.
15. European Centre for Disease Prevention and Control. ECDC HIV modelling tool [software application]. Version 1.3.0. Stockholm: European Centre for Disease Prevention and Control; 2017.
16. Johnson LF, May MT, Dorrington RE, Cornell M, Boulle A, Egger M, et al. Estimating the impact of antiretroviral treatment on adult mortality trends in South Africa: a mathematical modelling study. PLoS Med 2017; 14:e1002468.
17. Hall HI, Song R, Tang T, An Q, Prejean J, Dietz P, et al. HIV trends in the United States: diagnoses and estimated incidence. JMIR Public Health Surveill 2017; 3:e8–e18.
18. Stover J, Glaubius R, Mofenson L, Dugdale CM, Davies M-A, Patten G, Yiannoutsos C. Updates to the Spectrum/AIM model for estimating key HIV indicators at national and sub-national levels. AIDS 2019; 33: (Suppl 3): S227–S234.
19. Mahy M, Marsh K, Sabin K, Wanyeki I, Daher J, Ghys PD. HIV estimates through 2018: data for decision making. AIDS 2019; 33: (Suppl 3): S203–S211.
20. Maheu-Giroux M, Marsh K, Doyle CM, Godin A, Lanièce Delaunay C, Johnson LF, et al. National HIV testing and diagnosis coverage in sub-Saharan Africa: a new modeling tool for estimating the “first 90” from program and survey data. AIDS 2019; 33: (Suppl 3): S255–S269.
21. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infections: recommendations for a public health approach. Geneva: World Health Organization; 2016.
22. Goodrich B, Gabry J, Ali I, Brilleman S. rstanarm: Bayesian applied regression modeling via Stan. R package version 2.17.4. Pacific Grove, CA: StanCon; 2018.
23. Joint United Nationas Programme on HIV/AIDS (UNAIDS). Miles to go. Geneva, Switzerland: Joint United Nationas Programme on HIV/AIDS (UNAIDS); 2018.
24. Joint United Nationas Programme on HIV/AIDS (UNAIDS). How many poeple living with HIV access treatment. Geneva, Switzerland: Joint United Nationas Programme on HIV/AIDS (UNAIDS); 2016.
25. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data – United States and 6 dependent areas. HIV Surveil Suppl Rep 2019; 24:
26. Hess KL, Hall HI. HIV viral suppression, 37 states and the District of Columbia. J Commun Health 2018; 43:338–347.
27. Huerga H, Van Cutsem G, Ben Farhat J, Puren A, Bouhenia M, Wiesner L, et al. Progress towards the UNAIDS 90–90–90 goals by age and gender in a rural area of KwaZulu-Natal, South Africa: a household-based community cross-sectional survey. BMC Public health 2018; 18:303–1303.
28. Gaolathe T, Wirth KE, Holme MP, Makhema J, Moyo S, Chakalisa U, et al. Botswana's progress toward achieving the 2020 UNAIDS 90–90–90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV 2016; 3:e221–e230.
29. Porter K, Gourlay A, Attawell K, Hales D, Supervie V, Touloumi G, et al. Substantial heterogeneity in progress toward reaching the 90–90–90 HIV target in the WHO European Region. J Acquir Immune Defic Syndr 2018; 79:28–37.
30. Kisesa A, Chamla D. Getting to 90–90–90 targets for children and adolescents HIV in low and concentrated epidemics: bottlenecks, opportunities, and solutions. Curr Opin HIV AIDS 2016; 11: (Suppl 1): S1–S5.
31. Doshi RH, Sande E, Ogwal M, Kiyingi H, McIntyre A, Kusiima J, et al. Progress toward UNAIDS 90–90–90 targets: a respondent-driven survey among female sex workers in Kampala, Uganda. PLoS One 2018; 13:e0201352.
32. Amirkhanian YA, Kelly JA, DiFranceisco WJ, Kuznetsova AV, Tarima SS, Yakovlev AA, et al. Predictors of HIV care engagement, antiretroviral medication adherence, and viral suppression among people living with HIV infection in St. Petersburg, Russia. AIDS Behav 2018; 22:791–799.
33. Tokar A, Broerse JEW, Blanchard J, Roura M. HIV testing and counseling among female sex workers. AIDS Behav 2018; 22:2435–2457.
34. Dianatinasab M, Joulaei H, Shooshtarian S. Is UNAIDS 90–90–90 target a dream or a reality for Middle East and North Africa region on ending the AIDS epidemic? A review study. AIDS Rev 2018; 20:83–93.
35. Al Awaidy ST, Sharanya A. Successes and challenges of HIV/AIDS program in Oman. Oman Med J 2019; 34:1–8.
36. De Cock KM, Barker JL, Baggaley R, El Sadr WM. Where are the positives? HIV testing in sub-Saharan Africa in the era of test and treat. AIDS 2019; 33:349–352.
37. Weir SS, Baral SD, Edwards JK, Zadrozny S, Hargreaves J, Zhao J, et al. Opportunities for enhanced strategic use of surveys, medical records, and program data for HIV surveillance of key populations: scoping review. JMIR Public Health Surveill 2018; 4:e28–e128.
38. De Cock KM, El-Sadr WM, Ghebreyesus TA. Game changers: why did the scale-up of HIV treatment work despite weak health systems?. J Acquir Immune Defic Syndr 2011; 57:S61–S63.
39. Hayes RJ, Donnell D, Floyd S, Mandla N, Bwalya J, Sabapathy K, et al. Impact of a universal testing and treatment intervention on HIV incidence in Zambia and South Africa: results of the HPTN 071 (PopART) community-randomized trial. N Engl J Med 2019; 381:207–218.
40. Havlir DV, Balzer LB, Charlebois ED, Clark TD, Kwarisiima D, Ayieko J, et al. HIV testing and treatment with the use of a community health approach in Rural Africa. N Engl J Med 2019; 381:219–229.
41. Jiang J, Xu X, Guo W, Su J, Huang J, Liang B, et al. Dolutegravir (DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. AIDS Res Ther 2016; 13:30.
42. Cowan FM, Davey C, Fearon E, Mushati P, Dirawo J, Chabata S, et al. Targeted combination prevention to support female sex workers in Zimbabwe accessing and adhering to antiretrovirals for treatment and prevention of HIV (SAPPH-IRe): a cluster-randomised trial. Lancet HIV 2018; 5:e417–e426.
43. Dziva Chikwari C, Simms V, Busza J, Dauya E, Bandason T, Chonzi P, et al. Community health worker support to improve HIV treatment outcomes for older children and adolescents in Zimbabwe: a process evaluation of the ZENITH trial. Implement Sci 2018; 13:70.
44. Lifson AR, Workneh S, Hailemichael A, Demisse W, Slater L, Shenie T. Implementation of a peer HIV community support worker program in rural ethiopia to promote retention in care. J Int Assoc Provid AIDS Care 2015; 16:75–80.
45. World Health Organization. Data quality assessment of national and partner HIV treatment and patient monitoring data and systems implementation tool. Geneva, Switzerland: World Health Organization; 2018.
46. European Centre for Disease Prevention and Control; World Health Organization Regional Office for Europe. HIV/AIDS surveillancei n Europe. 2017 data. Copenhagen: WHO Regional Office for Europe; 2018.

90–90–90 estimates; HIV; HIV testing and treatment cascade; mathematical models; viral load suppression

Supplemental Digital Content

Copyright © 2019 Wolters Kluwer Health, Inc.